Targeted therapy and hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma in pediatric and adolescent patients: a pilot protocol results

Cover Page

Cite item

Full Text

Abstract

Background. Introduction a targeted drugs in a real clinical practice bring a vast improvement of prognosis in patients with relapsed and refractory (r/r) Hodgkin lymphoma (HL). But it is necessary to increase the experience in anti-CD30 monoclonal antibodies in combination with second-line chemotherapy in pediatric oncology/hematology.

Aim. To estimate the effectiveness of chemoimmunotherapy (ViGePD+BV scheme) in pediatric patients with r/r classical HL (cHL).

Materials and methods. From January 2018 to October 2022, 15 patients with r/r cHL received scheme ViGePD+BV. Programmed treatment included autologous stem cell transplantation (auto-SCT) in 11 (73%) patients. The potency assignment of antitumour treatment was performed with positron emission tomography/computed tomogtaphy (PET-CT).

Results. Complete metabolic response (PET-negative status) was achieved in all 15 (100%) patients after 4 inductive courses by ViGePD+BV scheme; 4-year relapse-free survival was 90.9±8.7%.

Conclusion. Our preliminary data of a pilot protocol of study a chemoimmunotherapy effectiveness for r/r cHL with brentuximab vedotin show a high potency of ViGePD+BV scheme in patients with r/r HL.

About the authors

Natalia S. Tsaplina

Blokhin National Medical Research Center of Oncology

Email: natalia_kulichkina@mail.ru
ORCID iD: 0000-0002-3511-357X

Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

Timur T. Valiev

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: timurvaliev@mail.ru
ORCID iD: 0000-0002-1469-2365

D. Sci. (Med.), Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

Kirill I. Kirgizov

Blokhin National Medical Research Center of Oncology

Email: k.kirgizov@ronc.ru
ORCID iD: 0000-0002-2945-284X

Cand. Sci. (Med.), Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

Svetlana R. Varfolomeeva

Blokhin National Medical Research Center of Oncology

Email: s.varfolomeeva@ronc.ru
ORCID iD: 0000-0001-6131-1783

D. Sci. (Med.), Prof., Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

References

  1. Lim SH, Johnson PWM. Optimizing therapy in advanced-stage Hodgkin lymphoma. Blood. 2018;131(15):1679-88.
  2. Hematologic malignancies: Hodgkin lymphoma. Eds A Engert, A Younes. Second edition. A Comprehensive Update on Diagnostics and Clinics. Berlin Heidelberg. Springer, 2015. doi: 10.1007/978-3-319-12505-3
  3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540-5.
  4. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065-71.
  5. NCCN (2019). NCCN clinical practice guidelines in oncology (NCCN guidelines®) for Hodgkin lymphoma V.2.2019. Available at: https://www.nccn.org/ professionals/physician_gls/pdf/hodgkins.pdf. Accessed: 01.10.2019.
  6. Eichenauer DA, Aleman BMP, Andre M, et al. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv19-29.
  7. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136-40.
  8. Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639-42.
  9. Hagenbeek A, Zijlstra JM, Plattel WJ, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed/refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Blood. 2018;132(Suppl. 1):2923.
  10. Garcia-Sanz R, Sureda A, De La Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30(4):612-20.
  11. Stamatoullas A, Ghesquieres H, Clement filliatre L, et al. Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study. Blood. 2019;134(Suppl. 1):132.
  12. Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428-39.
  13. Hatic H, Sampat D, Goyal G. Immune checkpoint inhibitors in lymphoma: challenges and opportunities. Ann Transl Med. 2021;9(12):1037. doi: 10.21037/atm-20-6833
  14. Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428-39. doi: 10.1200/JCO.2017.76.0793

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Distribution of patients with relapsed/refractory classical Hodgkin lymphoma (cHL) depending on the disease status, n (%).

Download (46KB)
Indexing metadata
3. Fig. 2. Therapy regimen in patients with cHL with late relapses.

Download (90KB)
Indexing metadata
4. Fig. 3. Therapy regimen for patients with early relapse and refractory cHL.

Download (101KB)
Indexing metadata
5. Fig. 4. Relapse-free survival in children with relapsed/refractory cHL treated with ViGePD+BV.

Download (34KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies